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Abstract
Marine seaweeds are a promising source of bioactive secondary metabolites that 
can be utilized in drug development and nutraceuticals. Diabetes mellitus is a lead-
ing non-communicable disease, and it is the third leading cause of death worldwide. 
Among the types of diabetes, type 2 became the major health problem as it is associ-
ated with severe health complications. Since available oral hypoglycemic drugs 
cause several adverse effects, it is worth searching for a natural cure with fewer or 
no side effects that may benefit patients with type 2 diabetes. Among the marine 
seaweeds, brown and red seaweeds are extensively studied for the anti-diabetic 
activity compared to the green seaweeds. Bioactive compounds present in marine 
seaweeds possess anti-diabetic potential through diverse mechanisms, mainly by 
reducing postprandial hyperglycemia and associated complication. Most of the 
studies emphasized that the marine seaweeds control the hyperglycemic condition 
by inhibiting carbohydrate hydrolyzing α-amylase,α glucosidase enzymes, and the 
inhibitory effect of dipeptide peptidase-4 that are involved in the degradation of 
incretins. Similarly, bioactive compounds in marine seaweeds can reduce diabetes 
complications by inhibiting angiotensin-converting enzymes, aldose reductase, 
protein tyrosine phosphatase 1B enzyme. This chapter focuses on the anti-diabetic 
potential of marine brown, green, and red seaweeds through different mechanisms.
Keywords: Marine seaweeds, microalgae, bioactive compound, diabetes, 
drug discovery, mechanisms of action
1. Introduction
The prevalence of diabetes has increased rapidly over the past few years, 
mainly in low to middle-income countries, and became one of the major causes of 
premature death worldwide. According to the WHO statistics, 422 million people 
were estimated as diabetes in 2014, and 1.6 million deaths were reported [1]. The 
International Diabetes Federation estimated that the world’s diabetic population has 
increased to 592 million by 2035. The largest number of diabetes cases was reported 
in the Western Pacific region (132 million), while 71.4 million diabetes cases were 
reported in the South Asian area [2].
Diabetes mellitus is a chronic metabolic disease characterized by hyperglycemia 
due to defects in insulin secretion, insulin action, or both. It is mainly classified 
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as insulin-dependent diabetes mellitus (Type 1 DM) and non-insulin-dependent 
diabetes mellitus (type 2 DM). Type 1 DM is associated with deficiency of insulin, 
which occurs due to the destruction of pancreatic ß-cells via an autoimmune pro-
cess. In contrast, type 2 DM is linked with insulin resistance, which reduces insulin 
utilization by peripheral tissues and results in hyperglycemia and obesity [3]. Type 
2 DM became a major health problem worldwide associated with microvascular and 
macrovascular health complications. Microvascular and microvascular complica-
tions include diabetic retinopathy, neuropathy, nephropathy, and cerebrovascular 
diseases, peripheral arterial diseases, respectively [4]. Therefore, natural thera-
peutic approaches [5] should be developed to maintain the blood glucose level and 
long-term complications in patients with type 2 DM.
As currently available treatment regimens for type 2 DM have adverse side effects, 
it is necessary to search for an effective drug that helps maintain the blood glucose 
level and complications in patients with type 2 DM. Even though most of the research-
ers focused on herbal medicine, none have a full beneficial effect on curing patients 
with type 2 DM [6]. Hence, it is worth emphasizing marine seaweeds as they have 
been identified as a rich source of promising bioactive compounds synthesized from 
their biochemical and physiological mechanisms. Besides, most marine seaweeds are 
survived in extremely harsh environments, which provide enormous potential to pro-
duce complex bioactive compounds to withstand extreme conditions. As a result, the 
composition of the bioactive compounds in marine seaweeds can vary depending on 
the geographic area and seasonal changes [7]. As most marine seaweeds are a potential 
source of bioactive compounds with various therapeutic effects, this chapter mainly 
emphasizes the pharmacological uses of marine algae as an anti-diabetic therapy.
2. Therapeutic targets for type 2 diabetes mellitus
As type 2 DM is a progressive disorder, the search for effective treatments is essen-
tial to maintain hyperglycemia and its associated diabetic complication. Insulin resis-
tance and impaired beta-cell function lead to hyperglycemia due to alteration in glucose 
homeostasis, which in turn cause loss of postprandial glucose control. Therefore, 
postprandial blood glucose maintenance is essential to manage the hyperglycemic 
condition and associated complications in type 2 diabetes patients [8]. Postprandial 
hyperglycemia in type 2 DM patients can be controlled by inhibiting metabolic 
enzymes such as α-amylase, α-glucosidase, dipeptide peptidase-IV, gut-derived peptide 
hormones (incretins), and glucagon-like peptide-1 hormone. The glucose-dependent 
insulinotropic peptide, aldose reductase, angiotensin-converting enzyme, and protein 
tyrosine phosphatase 1B are involved with diabetic complications [9].
Alpha-amylase and alpha-glucosidase are exo-acting glycoside hydrolase 
enzymes involved in carbohydrate digestion. Alpha-amylase is involved in the 
digestion of long-chain carbohydrates, while alpha-glucosidase catalyzes the end 
step hydrolysis of starch or disaccharides into simple glucose units. Therefore, 
inhibitors of these enzymes delay glucose absorption, reducing the postprandial 
blood glucose level [10].
Dipeptide peptidase-IV is a protease enzyme involved in the degradation of 
incretins, a group of metabolic hormones that stimulate ß cells of Langerhans’ islet 
to release insulin. Incretins are released after nutrient intake, and they delayed 
gastric emptying and decrease glucagon secretion in addition to stimulation of 
insulin secretion [11]. Contrarily, the incretin effect on insulin secretion gradually 
decreases once the patient becomes euglycaemic [12]. Hence, inhibitors of dipeptide 
peptidase IV are efficient therapeutic means to reduce the degradation of incretins, 
which help maintain hyperglycemic conditions in type 2 DM.
3
Advanced Pharmacological Uses of Marine Algae as an Anti-Diabetic Therapy
DOI: http://dx.doi.org/10.5772/intechopen.96807
Similarly, aldose reductase is a rate-limiting enzyme involved in the polyol 
pathway, which catalyzes glucose reduction into sorbitol in an NADPH-
dependent pathway. As the aldose reductase has broad substrate specificity, it 
binds with glucose and converts it into sorbitol once the hexokinase is saturated 
and the blood glucose level is high. As a result, produced sorbitol is accumulated 
within the cells and creates an osmotic effect, leading to cataracts and diabetic 
neuropathy [13, 14]. Thus, aldose reductase inhibitors prevent secondary diabetes 
complications.
Similarly, the angiotensin-converting enzyme plays a vital role in the renvital 
angiotensin-aldosterone system, a hormone system responsible for maintain-
ing the blood pressure and fluid balance in the body. Angiotensin-converting 
enzymes convert angiotensin I into angiotensin II, a potent vasoconstrictor that 
mainly acts on arterioles that stimulate the release of aldosterone from the renal 
cortex and improve sodium reabsorption from the kidney. Therefore, activation 
of the renin-angiotensin-aldosterone system leads to increased blood pressure, 
resulting in microvascular and macro-vascular complications in patients with 
type 2 DM. Thus, inhibitors of the angiotensin-converting enzyme reduce the 
long-term microvascular and macrovascular complications by lowering the 
arterial and venous blood pressure [15]. A study reported by Ustundag et al. [16] 
confirms that angiotensin-converting enzyme activity is increased in diabetic 
patients compared to normal individuals.
Correspondingly, protein tyrosine phosphatase IB (PTP IB) is a negative 
regulator of the insulin signaling pathway that dephosphorylate tyrosine residues 
in insulin receptor and insulin receptor substrate-1. Which in turn reduces insulin 
sensitivity [17]. Hence, inhibition of the PTP IB enzyme leads to lower blood 
glucose levels by enhancing insulin sensitivity. The stable hyperglycemic condi-
tion in type 2DM patients leads to the accumulation of advanced glycated end 
products in various tissues resulting in diabetic complications such as neuropathy, 
nephropathy, retinopathy, and other chronic diseases [18]. Therefore, the natural 
compounds, which inhibit the formation of advanced glycation end products, 
would be a promising therapeutic target to suppress the diabetic complications 
associated with glycated products.
3. Bioactive compounds present in marine seaweeds
Marine seaweeds are categorized into three algal classes; red (Rhodophyceae), 
green (Chlorophyceae), and brown algae (Phaeophyceae) based on the presence 
of natural pigments. Phaeophyceae contains brown color fucoxanthin pigment, 
whereas Rhodophyceae possess red color pigments phycoerythrin and phycocyanin, 
and Chlorophyceae is rich in green color pigment chlorophyll. Among the three 
varieties, most marine algae are referred to as “edible” that can be used for human 
consumption. Asians and South Africans mainly consume these edible seaweeds as 
a promising complementary and alternative medicine [19].
Recently, marine seaweeds have been identified as a rich source of bioactive 
secondary metabolites with human health benefits. In particular, polyphenols, 
sterols, alkaloids, flavonoids, tannins, proteins, peptides, essential fatty acids, 
enzymes, vitamins, and pigments are extensively synthesized by marine seaweeds. 
These compounds exhibit significant chemical and biological properties such as 
anti-diabetic, antioxidant, cytotoxic, anti-fungal, anti-bacterial, anti-coagulant, 
anti-inflammatory, and antiproliferative activities, etc., [19, 20]. The marine 
seaweeds are a rich source of sulfated polysaccharides (Figure 1), which have been 
reported to possess beneficial human effects. Fucoidan, alginates, and laminarans 
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are sulfated polysaccharide found in brown seaweeds and reported to exhibit 
anti-diabetic, antioxidant, and anti-inflammatory activities [21]. Carrageenans and 
agarans are sulfated polysaccharides found in red seaweeds. Similarly, ulvan is the 
sulfated polysaccharide found in green seaweeds [22]. The sulfated polysaccharides 
are known to possess anti-viral, anti-tumor, and anti-coagulant activities [23].
Marine seaweeds are rich in polyphenolic compounds, including flavonoids, 
bromophenols, phlorotannins, mycosprine-like amino acids, and phenolic ter-
penoids (Figure 2). The mycosprine-like amino acid is a small molecule with 
hydroxylated aromatic rings. Phlorotannins are polyphenolic metabolites found in 
brown seaweeds. They can be classified into six subgroups; fuhalols, phlorethols, 
fucophlorethols, and fucols, eckols, and carmalols based on their linkage between 
phloroglucinol units and hydroxyl groups. Flavonoids, bromophenol, phenolic 
terpenoids, phenolic acids, and mycosporine-like compounds are reported to 
possess antioxidant, anti-diabetic, anti-inflammatory, anti-allergic, and anticancer 
properties [24–26].
Figure 1. 
Chemical structures of sulfated polysaccharides present in marine seaweeds.
Figure 2. 
Organic structures of phlorotannins and bromophenols.
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Among the bioactive compounds present in marine seaweeds, marine algae-
derived accessory pigments are important as they possess beneficial biological 
activities [27]. Fucoxanthin is the most abundant accessory pigment found in 
brown seaweeds and reported to have potent biological activities such as anticancer, 
antioxidant, anti-diabetic activities due to the presence of unusual allenic bond and 
a 5, 6-monoepoxide in its structure [21]. Phycobiliproteins, a water-soluble acces-
sory pigment found in red seaweeds, can be divided into three main categories; phy-
cocyanins, allophycocyanins, and phycoerythrin. Phycoerythrins are abundantly 
found in red seaweeds and reported to possess immuno-modulating and anticancer 
activities. Similarly, chlorophylls are found in green seaweeds and are said to have 
antioxidant activity [27].
Similarly, marine algae-derived peptides have been identified to possess a wide 
range of biological activities such as antioxidant, anti-diabetic, anti-microbial, 
antihypertensive properties, etc. Hence, most algal-derived proteins have been 
widely used in food and pharmaceutical industries [28]. The protein content of the 
marine seaweeds differs depending on the seasonal period and type of species. The 
brown seaweeds usually contain low protein content compared to the red and green 
seaweeds. Despite this, some brown algal species such as Choonospora minima, 
Padina gymnospora, Dictyota menstrualis, and Sargassum vulgare possess high protein 
content up to 10–15%. According to the reported studies, green seaweed contains 
an average protein content level, ranging between 10–26%. In contrast, the highest 
protein content was reported in red seaweeds such as Phorphyra tenure and Palmaria 
palmata, which was around 47% [29].
4. Anti-diabetic potentials of marine algae
Marine seaweeds have been widely studied for their anti-diabetic potential 
through different mechanisms due to bioactive secondary metabolites. Several 
in-vitro and in-vivo studies have been conducted so far to confirm the hypoglycemic 
effect of marine algae in addition to its ability to suppress diabetic complications. 
This section emphasizes the anti-diabetic potential of marine brown, red, and green 
seaweeds through diverse mechanisms.
4.1  Inhibitory activity of carbohydrate hydrolyzing α-amylase and 
α-glucosidase enzymes
a. Brown seaweeds
Among the brown seaweeds, “Ecklonia” and “Eisenia” genera have been 
reported to exert hypoglycemic effects through α-amylase and α-glucosidase inhibi-
tory activities [30]. The observed hypoglycemic activity can be attributed to the 
presence of phlorotannins; eckol, dieckol, 6,6′-bieckol, phlorofucofuroeckol-A, and 
phloroglucinol, and 7-phloroeckol [31]. According to the reported studies, metha-
nol extract of Ecklonia cava exercises its hypoglycemic effects through the inhibi-
tory activity of α-glucosidase enzymes (IC50–10.7 μM), compared to the standard 
acarbose used. Similar results were reported with phlorotannins isolated from 
Ecklonia stolonifera against the α-glucosidase enzyme. Dieckol (IC50:1.61 μM) and 
phlorofucofuroeckol-A (IC50:1.37 μM) isolated from Ecklonia stolonifera reported 
to exhibit the potent inhibitory activity of α-glucosidase enzymes compared to 
the standard drug (IC50: 51.65 μM). Similarly, eckol (IC50: 11.16 μM) isolated from 
Ecklonia maxima demonstrated strong α-glucosidase inhibitory activity comparable 
to the isolated phloroglucinol (IC50: 1991 μM). Besides, Eisenia bicyclis from genus 
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Eisenia reported possessing 87% of inhibitory effect on α-amylase at 1 mM concen-
tration in addition to the inhibitory effect on α-glucosidase and advanced glycation 
end products. Moreover, isolated eckol (IC50: 22.78 μM), dioxinodehydroeckol (IC50: 
34.60 μM) and phloroglucinol (IC50: 141.18 μM) from Eisenia bicyclis exhibited 
potent α-glucosidase inhibitory activity [32].
A brown seaweed Sargassum hystrix reported to exhibit inhibitory effect 
on α-amylase IC50: 0:58 ± 0:01 mg/ml; IC50 acarbose: 0:53 ± 0:00 mg/ml) and 
α-glucosidase (IC50: 0:59 ± 0:02 mg/ml; IC50 acarbose: 0:61 ± 0:01 mg/ml) enzymes 
compared to the standard acarbose [33]. This was further confirmed by an in-vivo 
study using streptozotocin-induced rats and observed that the deduction of pre-
prandial (186.4 mg/ml) and postprandial (186.9 mg/ml) blood glucose levels at 
300 mg/kg concentration comparable to the standard drug glibenclamide (5 mg/
kg) (Pre-prandial;195.6 mg/ml; postprandial:104.8 mg/ml) without any adverse 
effects. Correspondingly, ethanol (150 mg/kg) and aqueous (300 mg/kg) extracts 
of Sargassum polycystum reported to reduce hyperglycaemic condition in diabetic 
rats [34]. Further studies has reported that a brown seaweed Ascophyllum nodosum 
effectively inhibited α-amylase (IC50: 0.1 μg/ml) and α-glucosidase enzymes ((IC50: 
19 μg/ml) due to the presence of phlorotannins [35].
b. Green seaweeds
Green seaweeds belong to the genus “Ulva.” They have been reported to possess 
hypoglycemic activity, and they have been used for various food dishes in Asians 
due to the presence of high soluble fiber content. The aqueous extract of green 
seaweeds Ulva lactuca (Inhibition-α-amylase: 83.4%; α-glucosidase: 61.81%) and 
Ulva reticulate (Inhibition-α-amylase: 89.1%; α-glucosidase: 76.02%) were effective 
against α-amylase and α-glucosidase enzymes at a concentration of 100 μg/ml after 
8 hours of extraction period at 37 °C in a water bath as it gets more time to release 
the phytochemicals and colloids to the extract [36]. Similarly, the crude extract of 
Ulva ohnoi exhibited α-amylase inhibition by 41.7% and complete α-glucosidase 
inhibition at 10 mg/mL [37].
The methanol extract of a green seaweed Chlorodesmis inhibited α-amylase 
enzyme by 72% at 500 μg/ml with IC50 of 408.9 μg/ml without any effect on 
α-glucosidase enzymes. Similarly, chloroform extract of Chaetomorpha aerea 
exhibited a potent inhibitory effect on α-amylase enzyme with IC50 of 147.6 μg/ml. 
Besides, methanol extract of green seaweeds Enteromorpha intestinalis (59%) and 
Cladophora rupestris (14%) exhibited a moderate and lower effect on the α-amylase 
inhibitory activity at a concentration of 500 μg/ml [38]. Moreover, crude extracts of 
green seaweeds Derbesia tenuissima and Oedogonium intermedium were reported 
to exhibit lower α-amylase (53.6% and 49.2%) and potent α-glucosidase (73.98% 
and 69.5%) inhibitory effect at a concentration of 10 mg/ml [39]. Further studies 
reported that the green seaweed Chlorella pyrenoidosa could suppress the hyper-
glycaemic condition by inhibiting α-amylase and α-glucosidase enzymes. Besides, 
a green seaweed Cladophora rupestris has been reported to exhibit a hypoglycemic 
effect through α-amylase and α-glucosidase inhibitory mechanisms [40].
c. Red seaweeds
Among the marine red seaweeds, the genus “Gracillaria” was reported to 
possess the hypoglycemic effect through the inhibitory effect on α-amylase and 
α-glucosidase enzymes. Gunathilaka et al, [41] reported that the ethyl acetate frac-
tion of red seaweed Gracillaria edulis exhibited potent α-amylase (IC50: 279.48 μg/
ml) and α-glucosidase (IC50: 87.92 μg/ml) inhibitory activity compared to the 
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standard acarbose (IC50amylase: 87.43 μg/ml; IC50glucosidase: 0.38 μg/ml) due to the pres-
ence of reported anti-diabetic compound 1H-Indole-2-carboxylic acid,6-(4-ethoxy 
phenyl)-3-methyl-4-oxo- 4,5,6,7-tetrahydro-isopropyl ester. Further studies 
reported that the aqueous extract of Gracillaria edulis inhibited the α-amylase 
and α-glucosidase enzyme by 87.86% and 79.55% at a concentration of 100 μg/ml. 
Similarly, Gracilaria corticata and Acanthophora spicifera had an inhibitory effect 
on α-amylase (84.66%; 54.73%) and α-glucosidase (73.53%; 46.86%) enzyme at a 
concentration of 100 μg/ml [36].
4.2 Inhibitory activity of dipeptidyl peptidase-IV (DPP-IV)
Dipeptidyl peptidase-IV (DPP-IV) is an enzyme involved in the degradation of 
incretin hormones, maintaining postprandial blood glucose levels. Among three 
types of seaweeds, brown seaweeds have been extensively reported to possess a 
dipeptidyl peptidase-IV (DPP-IV) inhibitory effect compared to red and green 
seaweeds [42].
a. Brown seaweeds
The brown seaweeds Padina sulcata, Sargassum binderi, and Turbinaria conoides 
have been reported to exhibit a potent inhibitory effect on the DPP-4 enzyme 
in a dose-dependent manner. The maximum inhibitory effect of Padina sulcata, 
Sargassum binderi, and Turbinaria conoides were observed as 83.09%, 81.75%, and 
76.20%, at a concentration of 10 mg/ml, respectively. Further, crude water extracts 
of the above three brown seaweeds could secrete glucagon-like peptide-1 (GLP-1) to 
a greater extent than prevent hyperglycaemic conditions [42]. Similarly, ethyl ace-
tate: methanol fraction (IC50: 0.013 mg/ml) of Sargassum wightii has been reported 
to exhibit an inhibitory effect on DPP-4 enzymes compared to the standard drug 
diprotein-A (IC50: 0.007 mg/ml) [43]. The methanol extract of Turbinaria ornate 
exhibited a strong inhibitory effect on the DPP-4 enzyme by 55.4% at 80 μg/ml than 
the standard drug diprotin A (65%) might attribute to the presence of fucoids and 
sulfated polysaccharides in T. ornata [44].
b. Green seaweeds
The previous study conducted by Chin et al. [42] reported the inhibitory 
activity of green seaweed Halimeda macroloba on the DPP-4 enzyme. Halimeda 
macroloba inhibited the DPP-4 enzyme by 60.53% at a 10 mg/ml concentration 
compared to the positive control Berberine (75.92% at 1 mg/mL). Moreover, crude 
water extract of H. macroloba was able to stimulate glucagon-like peptide-1  
(GLP-1) secretion.
c. Red seaweeds
The sulfated polygalactans isolated from red seaweeds Kappaphycus alvarezii and 
Gracilaria opuntia have been reported to possess the inhibitory effect on the DPP-4 
enzyme. According to the results, sulfated galactans isolated from Gracilaria opun-
tia (IC50 0.09 mg/mL) significantly inhibited the DPP-4 enzyme than the sulfated 
galactans of Kappaphycus alvarezii (IC50 0.12 mg/mL) compared to the standard 
diprotin A (IC50 1.54 mg/mL). The observed activity might be due to the reaction 
between functional groups of sulfated polygalactan with DPP-4 by H-bonding and 
hydrophilic interactions [45]. Similarly, aqueous, alkaline, and a mixture of aque-
ous/alkaline fractions of a red seaweeds Palmaria palmate have exhibited a potent 
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inhibitory effect on DPP-4 enzyme with IC50 of 2.52 ± 0.05 mg/ml, 4.60 ± 0.09 mg/
ml, and 4.24 ± 0.02 mg/ml respectively [46]. Further studies reported that the red 
seaweed Palmaria palmate’s protein hydrolysate had a potential inhibitory effect on 
the DPP-4 enzyme [40]]. These results confirmed the possible inhibitory effect on 
DPP-4 enzymes of red seaweed extracts.
4.3 Inhibitory activity of aldose reductase (AR)
a. Brown seaweeds
The ethyl acetate fraction of brown seaweed, Ecklonia stolonifera has been 
reported to possess a strong inhibitory effect on aldose reductase enzymes due to 
the presence of phlorotannins such as 7-phloroeckol and 2-phloroeckol in ethyl 
acetate fraction [47]. Similarly, phlorofucofuroeckol-A isolated from Eisenia bicyclis 
exhibited a potent inhibitory effect of aldose reductase enzyme (IC50: 6.22 μM). 
They also confirmed the inhibitory effect of fucosterol in the rat lens. Carotenoids 
isolated from Ecklonia stolonifera exhibited potent inhibitory activity on aldose 
reductase enzyme (IC50: 18.94 μM) compared to the standard positive control quer-
cetin (IC50: 1.34 μM). The presence of porphyrin derivatives (pheophytin-A and 
pheophorbide-A) in the dichloromethane fraction of Saccharina japonica caused 
excellent inhibitory effects on aldose reductase (AR) in rat lens [[48]. Moreover, 
fucoxanthin isolated from Undaria pinnatifida and Eisenia bicyclis reported acting 
as a competitive inhibitor on the aldose reductase enzyme [49].
b. Green seaweeds
The chloroform and ethanol fractions of green seaweed, Capsosiphon fulvescens 
showed a potent inhibitory action on the AR enzyme [50]. The authors further 
carried out isolation of compounds, and the isolated compounds (capsofulvesin A, 
B, and chalinasterol) demonstrated high inhibitory action on AR enzyme with IC50 
values of 52.53, 101.92, and 345.27 μM, respectively.
c. Red seaweeds
Regarding red seaweeds, the bromophenol compounds present in red seaweeds 
have been identified as effective therapeutic agents. The bromophenols such as 
bis (2,3,6-tribromo-4,5 -dihydroxy phenyl) methane, 2,2′,3,6,6′-pentabromo- 
3′,4,4′,5-tetrahydroxydibenzyl ether, and 2,2′,3,5′,6-pentabromo- 3′,4,4′,5-tetrahy-
droxydiphenylmethane isolated from red seaweed, Symphyocladia latiuscula are well 
known for their inhibitory effects on aldose reductase. This enzyme is responsible 
for the fructose formation in the polyol pathway [25].
4.4 Inhibitory activity of protein tyrosine phosphatase 1B (PTP 1B)
a. Brown seaweed
The brown seaweeds belonged to the genus “Sargassum” as reported to exhibit 
the potent inhibitory activity of PTP 1B enzyme due to the presence of second-
ary bioactive compounds. Ali et al. [51] reported that the hexane fraction (IC50: 
1.83 μg/ml) of Sargassum serratifolium strongly inhibited the PTP 1B enzyme than 
the standard ursolic acid (IC50: 1.12 μg/ml). During the compound isolation, three 
plastoquinones (sargachromenol, sargahydroquinoic acid, and sargaquinoic acid) 
were identified, and among them, sargahydroquinoic acid exhibited a potent PTP 1B 
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inhibitory effect (IC50:5.14 μg/ml). Similarly, the chloroform extract of Sargassum 
yezoense (54.4%), Sargassum fluvellum (36.1%), Sargassum horneri (46.2%), 
Sargassum sagmianum (21.4%), Sargassum hemiphyllum (44.1%), and Sargassum sili-
quastrum (14.8%) could inhibit PTP 1B enzymes at 15 μg/ml of concentration [52]. 
Further, the phlorotannins such as eckol, 7-phloroeckol, and phlorofucofuroeckol-A 
isolated from Ecklonia stolonifera, Ecklonia cava, and Eisenia bicyclis could act as non-
competitive inhibitors on PTP 1B enzyme [53]. Moon et al. [32] further confirmed 
the inhibitory effect of phlorofucofuroeckol-A (IC50: 0.56 μM), 7-phloroeckol 
(IC50: 2.09 μM), and eckol (IC50: 2.64 μM) isolated from Ecklonia stolonifera and 
Eisenia bicyclis. Moreover, fucosterol isolated from Eisenia bicyclis and Ecklonia 
stolonifera also showed PTP 1B inhibitory effect [54].
b. Green seaweeds
Several studies have been reported to elucidate the anti-diabetic potential of 
green seaweeds by enhancing insulin sensitivity through the mechanism of PTP 1B 
inhibition. Among the marine green seaweeds, Crude chloroform and methanol 
extract of a green seaweed Derbesia marina has been reported to exhibit an inhibi-
tory effect on PTP 1B enzyme by 61.7% and 80.65 respectively at a concentration of 
15 μg/ml. Further, the crude chloroform and methanol extract of edible green sea 
lettuce “Ulva pertusa” has exhibited potent PTP 1B inhibition at 15 μg/ml by 25.8% 
and 48.1%, respectively. Similarly, the crude chloroform and methanol extract of 
Enteromorpha linza (42.1%:35.4%) and Codium adhaerens (51.5%:71.2%) increased 
insulin sensitivity by inhibiting PTP 1B enzyme at 15 μg/ml concentration [52]. 
Further, the compounds isolated from the green seaweeds belonged to the genus “Caulerpa” 
had a potent anti-diabetic effect by the mechanism of PTP 1B inhibition. Racemosin C, 
Caulerpin, Caulerpic acid isolated from Caulerpa racemosa, and Caulersin isolated 
from Caulerpa serrulata have reported significant PTP1B inhibitor [55].
c. Red seaweeds
Most of the red seaweeds belonged to the genus “Chondus” exhibited anti-
diabetic activity via PTP 1B enzyme inhibition. According to the recorded studies, 
chloroform extract of chondus ocellanthus and chondus crispus inhibited PTP 1B 
enzymes by 41.5% and 27.6% at a concentration of 15 μg/ml. Similarly, red sea-
weeds belonged to the genus “Laurencia” had a potential inhibitory effect on PTP 
1B enzyme. The methanol extract of Laurencia okamurae (33.1%) and chloroform 
extract of Laurencia intermedia (43.3%) could inhibit PTP 1B enzyme at 15 μg/ml  
of concentration. In addition to that 15 μg/ml concentration of chloroform extract 
of Corallina pilulifera, Gymnogongrus flabelliformis, and Gracillaria textori inhib-
ited PTP 1B enzyme by 58.3%, 38.6%, and 24.9%, respectively [46]. Further, 
the compounds bromophenol and 3, 4-dibromo-5-(2-Bromo-3, 4-dihydroxy-
6-(ethoxymethyl)benzyl)benzene-1,2-diol isolated from red seaweed, Rhodomela 
confervoides could increase insulin sensitivity via inhibition of PTP 1B enzyme [40].
4.5 Inhibitory activity of angiotensin-converting enzymes (ACE)
a. Brown seaweeds
Phlorotannins eckol, phlorofucofuroeckol-A, and dieckol isolated from brown 
seaweed, Ecklonia stolonifera could inhibit angiotensin-converting enzyme with IC50 
values of 70:82 μM, 12:74 μM, and 34:25 μM, respectively. Among the isolated phlo-
rotannins, dieckol acted as a non-competitive inhibitor of ACE [56]. Similarly, the 
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phloroglucinol isolated from the ethyl acetate fraction of Sargassum (56.96 μg/ml)  
wightii significantly inhibited the ACE compared to the positive control captopril 
(51.79 μg/ml) [57]. An amino acid sequence isolated from edible brown seaweed, 
Undaria pinnatifida, could significantly inhibit angiotensin-converting enzymes [57]. 
The protein-derived hydrolysate of Undaria pinnatifida exhibited a potent antihyper-
tensive effect via inhibiting ACE [39]. Further, the enzymatic hydrolysate of Ecklonia 
cava has been reported to show a potent inhibitory effect on ACE with IC50 values 
from 2.33 up to 3.56 μg/mL [58].
b. Green seaweeds
Among the green seaweeds, few studies have been reported regarding the inhibi-
tory effect on the angiotensin-converting enzyme. Crude and saponified extracts of 
Ulva ohnoi, Derbesia tenuissima, and Oedogonium intermedium exhibited an inhibi-
tory effect on the angiotensin-converting enzyme. The crude extract of Ulva ohnoi, 
Derbesia tenuissima, and Oedogonium intermedium had a less potent inhibitory effect 
at 10 mg/ml. In contrast, the saponified extract of Ulva ohnoi, Derbesia tenuissima, 
and Oedogonium intermedium inhibited 1.9%, 1.47%, and 7.37% compared to the 
positive control captopril (6.15% inhibition at 200 μg/ml). However, carotenoids; 
siphonaxanthin, neoxanthin, 9′-cis-neoxanthin, loroxanthin, violaxanthin, lutein, 
siphonein, α-carotene, and β-carotene present in green seaweeds are found to be 
poor inhibitors of ACE [37]. Further, a protein-derived hydrolysate of an edible 
green seaweed Enteromorpha clathrata had a potent inhibitory effect on ACE [58].
c. Red seaweeds
The red seaweeds have been widely studied to elucidate the inhibitory effect on 
angiotthe ensin-converting enzyme, as it plays a crucial role in regulating blood 
pressure. According to the recorded studies, the aqueous extract at 20 °C of red 
seaweeds Lomentaria catenata, Lithophyllum okamurae, Ahnfeltiopsis flabelliformis, 
and Gracilaria textorii significantly inhibited the angiotensin-converting enzyme 
by 98.92%, 89.23%, 73.45%, and 65.40% at a lower concentration of 200 μg/ml.  
Similarly, the methanol extract at 700C of red seaweeds, Ahnfeltiopsis flabel-
liformis, and Laurencia okamurae has been reported to exhibit a strong inhibitory 
effect angiotensin-converting enzyme by 97.59% and 78.01% at a concentration 
of 200 μg/ml. Further, the methanol extract at 70 °C of red seaweeds Grateloupia 
filicina, Sinkoraena lancifolia, Grateloupia elliptica, Grateloupia lanceolata, 
and Laurencia okamurae exhibited an inhibitory effect on ACE by 83.14%, 
80.86%,68.13%, 89.04%, and 69.80% at 200 μg/ml of concentration [59]. This 
study revealed the presence of ACE like inhibitors in red seaweeds. Protein-derived 
hydrolysate in Palmaria palmate (red seaweed) showed marked antihypertensive 
activity. The antihypertensive activity was exerted via inhibition of angiotensin-
converting enzymes [46]. Further, an enzymatic hydrolysate of a red seaweed 
Pyropia columbina exhibited an inhibitory effect on the angiotensin-converting 
enzyme with an IC50 value of 1.2 mg/ml [58].
4.6  Inhibitory activity of the formation of advanced glycation end products 
(AGEs)
a. Brown seaweeds
Among the brown seaweeds, Ecklonia cava has been extensively studied for its 
anti-diabetic activity. The phlorotannins isolated from Ecklonia cava such as eckol 
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(IC50: 1:6 × 103 μM), phlorofucofuroeckol-A (IC50: 2:4 × 103 μM), fucofuroeckol A 
(IC50: 7:4 × 102 μM), and dieckol (IC50: 7:4 × 102 μM) could inhibit the formation 
of advanced glycation end products comparable to the standard drug aminoguani-
dine hydrochloride (IC50: 8:1 × 103 μM) [60]. Similarly, the phlorotannins isolated 
from methanol extract of brown seaweeds Sargassum polycystum (IC50: 35:245 μg/
ml), Turbinaria Ornate (IC50: 22:7 μg/ml), and Padina pavonica IC50: 15:16 μg/ml) 
had the ability to suppress the formation of advanced glycation end-products [61]. 
Further, phlorotannins extracted from the ethyl acetate fraction of Fucus vesiculosus 
(IC50: 0.045 mg/ml) significantly inhibited the AGEs formation compared to the 
phloroglucinol (IC50: 0.068 mg/ml) [62].
b. Green seaweeds
So far, minimal studies have been reported to demonstrate the inhibitory effect 
of green seaweeds on the formation of advanced glycation end products. The 
chloroform, ethanol, and butanol fractions of a green seaweed Capsosiphon fulves-
cens have been reported to exhibit an inhibitory effect on the formation of advanced 
glycation end-products [50].
c. Red seaweeds
Regarding the red seaweeds, the ethyl acetate fraction (IC50: 586.54 μg/ml) of 
Gracillaria edulis has been reported to exhibit the inhibitory effect on the forma-
tion of advanced glycation end products compared to the standard drug rutin 
(IC50: 11.55 μg/ml) [34]. Similarly, carrageenan extract from red algae could inhibit 
progressive glycation end product uptake by macrophage-like RAW 264.7 cells [63].
5. Conclusions
Recently, marine seaweeds have been extensively studied for their therapeutic 
effects due to promising bioactive compounds. Among the non-communicable 
diseases, diabetes mellitus is the third leading cause of death associated with 
vascular complications. As it is a progressive disorder, it is necessary to search for 
an adequate drug for natural resources with minimum side effects. Therefore, 
this chapter illustrates the different anti-diabetic mechanisms of marine seaweed 
extracts and their bioactive compounds.
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